My mistake, so it is. There should be similar annual/interim reports for the IT though. That said, it is complicated by the whole name change from Witan Pacific.
The latest annual report for Witan can be found here, but it’s not much use because it was previously focused more on the pacific region than China. I imagine BGCG will be very similar to the Baillie Gifford OEIC for China though.
LSE:ERIS (Erris Resources plc (to be renamed as Zinnwald Lithium plc from Admission))
LSE:SBI (Source Bio International plc)
LSE:BGCG (Baillie Gifford China Growth Trust) - not available in IB yet
NDAQ:AVIR (Atea Pharmaceuticals) - not available in IB yet
NDAQ:IKT (Inhibikase Therapeutics) - not available in IB yet
NDAQ:GMVD (G Medical Innovations Holdings Ltd.) - not available in IB yet
NYSE:LU (Lufax Holding Ltd)
NYSE:SQZ (SQZ Biotechnologies)
NDAQ:NOAC (Natural Order Acquisition Corp.) - not available in IB yet